Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...

The latest recall affects a generic versions of the statin medication Atorvastatin Calcium, a medication taken by around 47 ...

New York, USA, October 22nd, 2025, FinanceWire BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company ...

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb ...

With an aim to curb misuse and over-the-counter sale of high-alcohol oral preparations, through a recent Gazette notification ...

The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

A provision of the summer’s One Big Beautiful Bill Act bumping a slew of orphan drugs from Medicare price negotiation is ...

The large-mass animal crossover bioequivalence study will commence in the next two to three weeks and will be carried out ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.

Asahi Kasei expands its Sonanos excipient portfolio with two new specialty grades designed to improve injectable drug formulations.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...